Their studies explored multiple site-specific phosphoproteins in vivo in cell lines containing the EGFR tyrosine kinase domain mutations and provided the key insights into the potential drug targets for NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.